• home
  • partners
  • contact
  • Uitgaven
  • partners
  • Vacatures
  • Nieuws
  • Agenda
  • Opleidingen
    • Nucleair Radioloog
    • Klinisch fysicus
    • Medisch nucleair werker
    • Ziekenhuisapotheker
    • Radiochemicus
  • Adverteren
  • Redactie
home > Uitgaven > Jun '23. [131I]mIBG therapy in neuroblastoma – 35 Years of experience

Jun '23. [131I]mIBG therapy in neuroblastoma – 35 Years of experience

Auteur

A. Samim, G. Bleeker, K.C.J. Kraal, Prof. M.M. van Noesel, B. de Keizer, G.A.M. Tytgat

Vakblad

TvNG

Editie

2023-02, juni

Thema

Radionuclidentherapie


 

Download nu

De PDF wordt automatisch gedownload. Afhankelijk van uw browser of device opent deze zich automatisch of staat in de downloads van uw browser

  • Inhoudsopgave

Neuroblastoma is the most common extracranial solid malignancy of childhood. Approximately half of patients have high-risk neuroblastoma (HR-NBL), typically presenting with widespread metastatic disease at diagnosis. Despite aggressive multimodality treatment, patients with HRNBL have a long-term survival of less than 50%, due to a high relapse/progression rate and therapy-resistant disease.

Hoofdpartner

Business partners

  • Copyright
  • Algemene voorwaarden
  • Disclaimer
  • Privacy
  • Sitemap
  • Colofon

© Kloosterhof Neer BV